obicetrapib
Sponsor Newamsterdam Pharma CO N.V. · listed as NAMS
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
Next catalyst
Event typeREADOUT
Expected date2026-11-30
As disclosedNov 2026
Date precisionmonth
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05202509
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorNewAmsterdam Pharma
Listed asNAMS
Condition(s)Atherosclerotic Cardiovascular Disease
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More NAMS catalysts